Entitles the owner of the right to market a non-steroidal anti-inflammatory drug that contains a previously patented active agent, that has been reviewed by the Food and Drug Administration (FDA) for more than 120 months as a new drug application, and that was approved as safe and effective by the FDA on October 29, 1992, to exclude others from making, using, offering for sale, selling, or importing such active agent for two years beginning October 29, 1997.

Applies the prohibition on infringement of patents to such entitlement. Prohibits submission of an application under the Federal Food, Drug, and Cosmetic Act for introduction into interstate commerce of a drug claimed in a patent, or the use of which is claimed in a patent, before the expiration of such entitlement.